Journal
JOURNAL OF CANCER
Volume 2, Issue -, Pages 331-332Publisher
IVYSPRING INT PUBL
DOI: 10.7150/jca.2.331
Keywords
B-cell Malignancies; CART-19; Chimeric Antigen Receptor Therapy
Categories
Funding
- Leukemia & Lymphoma Society [7000-02]
- NIH [K24 CA11787901]
Ask authors/readers for more resources
We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
